Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director · Chief Executive Officer | February 26, 2021 | March 02, 2021 |
| NEOGENOMICS INCNEO · Entity 2096 | Director · Chief Executive Officer | March 01, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 470,605 |
Ending reported balance
After 2021-02-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-26 · Sale · Disposed 8,093 · Balance 493,187 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019. Row 2 · 2021-02-26 · Sale · Disposed 22,582 · Balance 470,605 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
NEOGENOMICS INC
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 368,051 |
Reported balance
After 2022-03-01 transaction · row 1
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 142,457 · Balance 368,051 F1: On March 1, 2022, Mr. Mallon was granted 142,457 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2029-03-01 | Direct | 347,777 |
Reported balance
After 2022-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-01 · Grant · Acquired 347,777 · Balance 347,777 F3: On March 1, 2022, Mr. Mallon was granted 347,777 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.34 · Expires 2028-04-19 | Direct | 151,016 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 151,016 F2: On April 19, 2021, Mr. Mallon was granted 151,016 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 1, 2022, Mr. Mallon was granted 142,457 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.
F2: On April 19, 2021, Mr. Mallon was granted 151,016 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F3: On March 1, 2022, Mr. Mallon was granted 347,777 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 4, 2022 00:59 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 347,777 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001077183-22-000043 · wf-form4_164635552579023.xml · derivative · entry 3 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,777 Underlying: Common Stock · 347,777 shares Expires 2029-03-01 F3 · derivative.exercise_date: On March 1, 2022, Mr. Mallon was granted 347,777 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:59 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 142,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000043 · wf-form4_164635552579023.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,051 F1 · shares: On March 1, 2022, Mr. Mallon was granted 142,457 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| December 30, 2021 Filed Dec 30, 2021 23:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 152,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000278 · wf-form4_164090548763134.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,594 F1 · kind: On December 30, 2021, Mr. Mallon was granted 152,858 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022. Read SEC document |
| December 06, 2021 Filed Dec 6, 2021 21:16 UTC | NEOGENOMICS INC NEO · Entity 2096 | PurchaseCommon Stock | 17,000 | $30.63 | $520,710.00 |
DisclosureSEC source: 0001077183-21-000256 · wf-form4_163882538985808.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,736 Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 151,016 | $0.00 Strike: $49.34 | $0.00 |
DisclosureSEC source: 0001077183-21-000111 · wf-form4_161904358115470.xml · derivative · entry 2 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,016 Underlying: Common Stock · 151,016 shares Expires 2028-04-19 F1 · derivative.exercise_date: On April 19, 2021, Mr. Mallon was granted 151,016 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 22:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 55,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000111 · wf-form4_161904358115470.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,736 Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 22,582 | $9.11 | $205,722.02 |
DisclosureSEC source: 0001209191-21-016044 · doc4.xml · nonDerivative · entry 2 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,605 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 8,093 | $9.11 | $73,727.23 |
DisclosureSEC source: 0001209191-21-016044 · doc4.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 493,187 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019. Read SEC document |
| May 11, 2020 Filed May 13, 2020 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 23,206 | $10.35 | $240,182.10 |
DisclosureSEC source: 0001209191-20-028900 · doc4.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 501,280 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 21:29 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 221,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014467 · doc4.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,486 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to approximately 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 24, 2020 Filed Feb 25, 2020 21:45 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1 | $11.25 | $11.25 |
DisclosureSEC source: 0001209191-20-012528 · doc4.xml · nonDerivative · entry 2 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,425 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:45 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 7,983 | $11.63 | $92,842.29 |
DisclosureSEC source: 0001209191-20-012528 · doc4.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,426 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 423,049 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-19-023482 · doc4.xml · derivative · entry 4 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,049 Underlying: Class A Common Stock · 423,049 shares Expires 2029-04-01 F5 · derivative.exercise_date: The option, granted as a new Chief Executive Officer award, vests as to 25% of the shares of Class A Common Stock on the first anniversary of January 4, 2019 and 1/48th of the shares of Class A Common Stock vest each month thereafter for the next 36 months. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 21,203 | Not disclosed Strike: $10.97 | Not disclosed |
DisclosureSEC source: 0001209191-19-023482 · doc4.xml · derivative · entry 3 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,729 Underlying: Class A Common Stock · 21,203 shares Expires 2029-01-09 F3 · derivative.exercise_price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F3 · shares: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F3 · price: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F4 · derivative.exercise_date: The option, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on the first anniversary of January 4, 2019 and 1/48th of the shares of Class A Common Stock vest each month thereafter for the next 36 months. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 206,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-023482 · doc4.xml · nonDerivative · entry 2 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,409 F2 · kind: The restricted stock unit award, granted as a new hire award to the new Chief Executive Officer, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 23:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 11,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-023482 · doc4.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,536 F1 · price: In connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. from Ironwood Pharmaceuticals, Inc. ("Ironwood"), the reporting person received 11,500 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. The restricted stock units are subject to vesting conditions consistent with the terms of the existing Ironwood restricted stock units held by the reporting person prior to the Separation. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 21:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 171,526 | $0.00 Strike: $12.32 | $0.00 |
DisclosureSEC source: 0001209191-19-003409 · doc4.xml · derivative · entry 2 Mallon Mark · CIK 0001763533 · Executive Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,526 Underlying: Class A Common Stock · 171,526 shares Expires 2029-01-09 F2 · derivative.exercise_date: The option, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on the first anniversary of January 4, 2019 and 1/48th of the shares of Class A Common Stock vest each month thereafter for the next 36 months. Read SEC document |
| January 09, 2019 Filed Jan 11, 2019 21:13 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 93,036 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003409 · doc4.xml · nonDerivative · entry 1 Mallon Mark · CIK 0001763533 · Executive Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,036 F1 · kind: The restricted stock unit award, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.